2020 ASCO Virtual Direct™ Highlights
Lung
2020 ASCO Virtual Direct™ Highlights
FDA Approved Pralsetinib (BLU-667) in RET+ mNSCLC: ARROW Trial Overview
FEATURING
Michael Shafique
- 35 views
- April 13, 2021
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on ctDNA: Can We Use ctDNA as a Marker of MRD Following Definitive Treatment in Localized NSCLC? Is the Absence of Detectable BRAFV600 ctDNA at Baseline Associated With Improved PFS and OS in Pts Receiving Dabrafenib and Trametinib?
FEATURING
Martin Dietrich
- 125 views
- November 11, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Updates on IO in ES-SCLC: Should You Recommend 1L IO+EP Combination Instead of EP Alone?
FEATURING
John Vu
- 78 views
- September 28, 2020
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Highlights on mNSCLC: Will the Efficacy of T-DXd in HER2+ Disease Add HER2 Mutation to the List of Essential NSCLC Biomarkers? OS With Bevacizumab + Erlotinib in EGFR+ NSCLC - Does It Change the Role of Osimertinib in 1L Therapy?
FEATURING
Michael Shafique
- 87 views
- September 25, 2020